Introduction
NSCLC, tumor, lung cancer
LUNG CANCER, TUMOR, NSCLC, NON-SMALL CELL LUNG CANCER
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer casesMore than 15% of patients diagnosed with NSCLC are in locally advanced stageAfatinib is a second-generation This work, the single-arm phase II clinical trial (TEAM-LungMate 004), aims to assess the efficacy and safety of neoadjuvant Afatinib for stage III NSCLCm+. The trial successfully achieves the pre-specified primary endpoint with an objective response rate (ORR) of 70.2%. Moreover, the study delves into investigating the molecular characteristics that are associated with the efficacy of Afatinib, as well as exploring the dynamic changes occurring in the tumor microenvironment following Afatinib treatment through bulk RNA sequencing (RNA-seq) on baseline and post-treatment samples obtained from the trial participants.